Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Ultimately, investing in your health with the right treatment can lead to significant long-term benefits
From a cardiovascular perspective, the glucagon components contribution to increased energy expenditure and fat oxidation translates to greater reductions in the visceral fat deposits most strongly associated with cardiovascular disease
Moreover, fasting hyperglycaemia was responsible for 2.3 million cardiovascular deaths worldwide in 2021 [2]
REDEFINE Clinical Trial Program Overview The REDEFINE program is a comprehensive Phase 3 clinical trial initiative evaluating CagriSema across diverse populations and settings: Expected Completion: The REDEFINE program is anticipated to complete enrollment and report results between 2024-2026, providing comprehensive data to support regulatory submissions worldwide
Studied for some of the largest body-weight reductions reported for the class
